This is one of the preliminary results of an initiative of an industry-wide consortium including leaders from Johnson & Johnson, Bard and Novartis to address the opportunities/challenges for digital technologies in clinical development. This white paper is part of the series of results of Digital Trials…
Digital Trials: Other Results
The next step in the study is looking at the practical applications of digital technologies to collect real-time, uncorrupted data.
To stay up to date, and receive other results, please click on the button below. Note: you’ll be asked to provide your brief (“one click”) opinion, and will then be given access to more research results.